Free Trial

PACS Group (NYSE:PACS) Given New $64.00 Price Target at Royal Bank Of Canada

PACS Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Royal Bank of Canada raised its PACS Group price target to $64 from $57 and maintained an “outperform” rating, implying about 31% upside from the cited share price.
  • Analyst sentiment is broadly positive: seven analysts rate the stock Buy and one Hold, with a consensus “Moderate Buy” rating and an average target of $62.50.
  • PACS beat quarterly expectations, reporting EPS of $0.63 versus $0.58 expected and revenue of $1.50 billion versus $1.46 billion forecast.
  • Five stocks to consider instead of PACS Group.

PACS Group (NYSE:PACS - Get Free Report) had its price objective lifted by investment analysts at Royal Bank Of Canada from $57.00 to $64.00 in a research report issued on Monday, Benzinga reports. The firm currently has an "outperform" rating on the stock. Royal Bank Of Canada's target price points to a potential upside of 30.85% from the stock's current price.

A number of other research firms have also recently issued reports on PACS. Zacks Research cut PACS Group from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 9th. Stephens raised their target price on PACS Group from $60.00 to $64.00 and gave the stock an "overweight" rating in a research report on Thursday, November 5th. Oppenheimer lifted their price target on shares of PACS Group from $48.00 to $57.00 and gave the stock an "outperform" rating in a research note on Monday, August 10th. Weiss Ratings raised shares of PACS Group from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. boosted their price target on shares of PACS Group from $47.00 to $58.00 and gave the company an "overweight" rating in a report on Friday, September 4th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $62.50.

View Our Latest Analysis on PACS

PACS Group Stock Performance

PACS traded up $0.59 on Monday, hitting $48.91. 55,705 shares of the stock traded hands, compared to its average volume of 891,898. PACS Group has a 52 week low of $12.71 and a 52 week high of $51.68. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $7.76 billion, a PE ratio of 27.82, a P/E/G ratio of 1.57 and a beta of -0.14. The business has a fifty day moving average price of $45.25 and a two-hundred day moving average price of $40.38.

PACS Group (NYSE:PACS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.58 by $0.05. PACS Group had a return on equity of 31.98% and a net margin of 4.87%. The firm had revenue of $1.50 billion during the quarter, compared to analysts' expectations of $1.46 billion. On average, research analysts predict that PACS Group will post 2.05 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jason Murray sold 19,235 shares of PACS Group stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $50.64, for a total transaction of $974,060.40. Following the completion of the transaction, the chief executive officer directly owned 53,934,866 shares of the company's stock, valued at $2,731,261,614.24. This trade represents a 0.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Hancock sold 186,696 shares of PACS Group stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $50.45, for a total transaction of $9,418,813.20. Following the completion of the transaction, the director owned 53,318,884 shares of the company's stock, valued at $2,689,937,697.80. This trade represents a 0.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,697,064 shares of company stock worth $78,104,889. Company insiders own 70.10% of the company's stock.

Institutional Trading of PACS Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PACS. Financial Management Professionals Inc. raised its stake in shares of PACS Group by 54.9% during the second quarter. Financial Management Professionals Inc. now owns 663 shares of the company's stock worth $28,000 after buying an additional 235 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in PACS Group in the third quarter valued at approximately $34,000. GK Wealth Management LLC bought a new stake in shares of PACS Group during the 3rd quarter valued at $41,000. USA Financial Formulas bought a new stake in shares of PACS Group during the 3rd quarter valued at $46,000. Finally, KBC Group NV bought a new stake in shares of PACS Group during the 1st quarter valued at $42,000.

About PACS Group

(Get Free Report)

PACS Group, Inc. is a post-acute healthcare provider that operates skilled nursing and rehabilitation facilities. Its services include nursing care, physical and occupational therapy, and support for patients recovering from illness or injury, as well as care for people with ongoing or long-term needs. Founded in 2013, the company has expanded its network of facilities across the United States. Its operations are organized through affiliated entities, with care and services tailored to the needs of residents and patients in the communities it serves.

Featured Articles

Analyst Recommendations for PACS Group (NYSE:PACS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in PACS Group Right Now?

Before you consider PACS Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PACS Group wasn't on the list.

While PACS Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines